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Abstract
Summary The recommended intake of vitamin D-fortified
dairy products can substantially decrease the burden of osteo-
porotic fractures and seems an economically beneficial strat-
egy in the general French population aged over 60 years.
Introduction This study aims to assess the public health and
economic impact of vitamin D-fortified dairy products in the
general French population aged over 60 years.
Methods We estimated the lifetime health impacts expressed
in number of fractures prevented, life years gained, and
quality-adjusted life years (QALY) gained of the recommend-
ed intake of dairy products in the general French population
over 60 years for 1 year (2015). A validated microsimulation
model was used to simulate three age cohorts for both women
and men (60–69, 70–79, and >80 years). The incremental cost
per QALY gained of vitamin D-fortified dairy products com-
pared to the absence of appropriate intake was estimated in
different populations, assuming the cost of two dairy products
per day in base case.
Results The total lifetime number of fractures decreased by
64,932 for the recommended intake of dairy products in the
general population over 60 years, of which 46,472 and 18,460
occurred in women and men, respectively. In particular,
15,087 and 4413 hip fractures could be prevented in women
and men. Vitamin D-fortified dairy products also resulted in
32,569 QALYs and 29,169 life years gained. The cost per
QALY gained of appropriate dairy intake was estimated at
€58,244 and fall below a threshold of €30,000 per QALY
gained in women over 70 years and in men over 80 years.
Conclusion Vitamin D-fortified dairy products have the po-
tential to substantially reduce the burden of osteoporotic frac-
tures in France and seem an economically beneficial strategy,
especially in the general population aged above 70 years.
Keywords Cost-effectiveness . Dairy products . Fractures .
France . Public health
Introduction
Osteoporotic fractures represent a major public health prob-
lem that leads to increased morbidity, mortality, and health
care costs [1]. In France, it was estimated that 50,215 and
15,482 hip fractures occurred in the year 2013 in women
and men, respectively [2]. In another report prepared in col-
laboration between the International Osteoporosis Foundation
(IOF) and the European Federation of Pharmaceutical
Industry Associations (EFPIA), the economic burden of inci-
dent and previous fragility fractures was estimated at €4853
million in France and fractures accounted for 139,400 quality-
adjusted life years (QALYs) lost in 2010 [1].
Calcium and vitamin D are crucial for bone health and
fracture prevention. A European consensus group recom-
mends adequate vitamin D intake of 800 IU/day and calcium
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intake of 1000 mg per day [3]. Several studies reported a high
prevalence of vitamin D insufficiency and low dietary calcium
in many elderly men and women [4, 5]. In France, only 20 %
of women consumed ≥1000mg of calcium per day [6] and the
prevalence of vitamin D inadequacy is >85 % in women with
osteoporosis or osteopenia aged over 50 years as well as in
elderly subjects above 80 years [5, 7]. Several studies have
reported that the current intake of calcium and vitamin D is far
from optimal in France [6, 8–10]. By example, one large scale
study estimated that, respectively, 73.9 and 86.5 % of elderly
women have low dietary intakes of vitamin D and low dietary
calcium intakes [8]. It is therefore important to adequately
supplement elderly patients with calcium and vitamin D [3,
11]. The use of dietary sources of calcium has been recom-
mended as the preferred option by the European guidance for
the diagnosis and management of osteoporosis [12]. The
French National Nutrition and Health Program recommends
the consumption of three dairy product servings/day for adults
(3 to 4 for over 55-year-olds) but only 29 % of French adults
meet this recommendation [13].
Assessing the public health and economic impact of the
recommended intake of dairy products and vitamin D would
be important to help policy makers in evaluating and making
decisions about preventive programs, especially in the context
of limited health care resources. To date, relatively few studies
have assessed the public health and economic impact of vita-
min D-fortified dairy products given to the general elderly
population [14–17]. These studies suggest the public health
and economic value of fortified dairy products. To our knowl-
edge, no study has been conducted to assess the public health
and economic impact of vitamin D-fortified dairy products for
fracture prevention in France.
This study therefore aimed to estimate the public health and
economic impact of dairy products supplemented with vita-
min D in the general population aged over 60 years in France.
Specifically, we estimated the impact of the recommended
intake of fortified dairy products on the number of fractures
prevented, on life years gained, on gained, and evaluated the
cost-effectiveness of fortified dairy products compared with
the absence of appropriate intake in terms of cost per QALY
gained.
Methods
We used a previously validated Markov microsimulation
model [18] to estimate the public health and economic impact
of the recommended intake of vitamin D-fortified dairy prod-
ucts in France compared to the absence of appropriate intake.
The model simulates over lifetime the number of fractures
(hip, clinical vertebral, wrist, other and all), life years,
QALY, and total health care costs. The more recent version
of the model with a 6-month time horizon was used in this
study [17, 19] and was adjusted to the French setting. In a
Markov model, patients transit between different health states
(no fracture, fractures, post fracture, and death) according to
transition probabilities. Description of the model can be found
in previous publications (9, 10).
Analyses were conducted in the general population in
France aged over 60 years, including women and men. In both
genders, three age cohorts (60–69 years, 70–79 years, 80+)
were used to estimate outcomes using the software TreeAge
Pro 2011 (TreeAge Pro Inc., Williamston, MA). For each
cohort, we simulated 1,000,000 microsimulations. The base
year of the analysis was 2015. We therefore estimated the
impact of vitamin D-fortified dairy products to all individuals
for 1 year (2015 base case) and estimated the lifetime effect of
this intervention. Based on the distribution of the population
in each cohort that was obtained from the National Institute of
Statistics and Economic Studies (INSEE) [20] (see Table 1),
we then calculated using an Excel sheet, the total costs, and
outcomes in the general French population aged above
60 years. Projections for the years 2025 and 2050 were also
done using populations projections from INSEE [21] to eval-
uate the effects of demographic changes on the benefits of the
strategy.
Incidence of hip fractures in the general population was
derived from the recent study of Briot et al. [2] using data
from the year 2013 (see Table 2). As no data for the incidence
of other osteoporotic fractures (i.e., clinical vertebral, wrist,
and other fractures) are available in France, we applied the
age-specific ratio incidence from other countries in line with
previous publications [1]. In addition, the model assumed an
increased risk of fracture for individuals who had a prior frac-
ture at the same location [18]. Mortality data for the general
population were derived from INSEE for the years 2011–2013
[22]. According to data from a meta-analysis [23], hip frac-
tures increased female (male) death probabilities by 4.53
(5.75) in the first 6 months following the fracture, by 1.75
(2.31) in the period 6–12 months, and by 1.78 (1.69) in sub-
sequent years. The same impact was assumed after hip and
clinical vertebral fractures. We conservatively assumed that
only 25 % of the excess mortality following a hip or vertebral
fracture could be directly or indirectly attributable to the frac-
tures themselves. Utility values in the general French popula-
tion (used for patients without fracture) was estimated at 0.766
[24]. Relative reductions due to fractures in the year following
the fracture and in subsequent years were derived from a sys-
tematic review [25].
The health care perspective was used for the cost estima-
tion. As productivity losses are limited in patients over
60 years, the perspective is quasi-societal. The cost of hip
and wrist fractures was derived from the study of Bouee
et al. [26]. The cost of clinical vertebral fracture was derived
from a previous cost-effectiveness analysis in France [27].
The cost of other fractures was assumed to represent 17.6 %
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from the cost of hip fracture, in line withMelton et al. [28]. All
costs were expressed in €2015 using the national price index
(health index) and a discount rate of 3 % was used for both
costs and outcomes. The costs of fractures for the year 2015
were thus estimated at €11,970, €6201, €2124, and €2093 for
hip, clinical vertebral, wrist, and other fractures, respectively.
Hip fractures are also associated with long-term costs. These
long-term costs were based on the proportion of patients being
institutionalized after the fracture. Based on the study of
Drame et al. [29], 20.1 % of patients with a hip fracture were
institutionalized after a hip fracture in French population aged
above 75 years. For patients aged between 60 and 74 years,
we conservatively assumed that 10 % of patients were insti-
tutionalized after a hip fracture in line with international stud-
ies [1]. The yearly costs of nursing home were estimated at
€37,255 based on national data.
The effect of adequate intake of calcium and vitamin Dwas
derived from a recent Cochrane Review [30]. Based on this
review, the fracture incidence reduction of vitamin D and cal-
cium intervention was 16, 14, 11, and 11 % for hip fracture,
clinical vertebral, wrist, and other fractures, respectively.
These estimations are slightly more conservative that those
used in previous economic evaluations of calcium and vitamin
D [14, 17] (estimated at 18, 13, 20, and 20%, respectively). In
the model, people only received fortified dairy products for
1 year (2015 in base case), and no further effect was assumed
after the year of treatment. The model has however a lifetime
horizon to capture the long-term benefits of preventing frac-
tures in the year of the intake of fortified dairy products.
The cost of one vitamin D-fortified dairy product was esti-
mated at €0.27 in France based on the prices of two leading
industry suppliers from three French cities for vitamin D-
enriched milk and yogurt (on the date of 20/01/2016). Based
on current consumption of calcium and vitamin D in France
and European recommendation on adequate levels [3, 6], two
vitamin D fortified dairy products per day are needed to
achieve optimal intake of calcium and vitamin D. We there-
fore assumed the price of two dairy products per day in the
base case for the economic analysis.
Presentation of results and sensitivity analyses
We estimated the lifetime number of fractures prevented (per
type), life years gained, and QALY gained of recommended
dairy intake versus absence of appropriate intake for the year
2015. Data are presented for the overall population aged over
60 years as well as per age group and gender. Incremental
cost-effective ratios (ICERs) were estimated for the recom-
mended intake of fortified dairy products versus usual care.
ICERs are defined as the differences in costs between alterna-
tives divided by their differences in outcomes (expressed in
QALYs). An ICER represents therefore, the cost per QALY
gained of recommended intake of fortified dairy products ver-
sus usual care. Projections for the years 2025 and 2050 were
also conducted to evaluate the effects of demographic changes
on the potential benefits of the strategy.
We conducted 11 additional one-way sensitivity analyses
(SA) to assess the impact of parameters on the lifetime number
of fractures prevented and QALY gained, and on the cost per
QALY gained of the recommended dairy intake. SA1: all
fracture risk +25 %; SA2: all fracture risk −25 %; SA3: ther-
apy efficacy +25 %; SA4: therapy efficacy −25 %; SA5: ther-
apy cost +50 % (three dairy products per day); SA6: therapy
cost −50 % (one dairy product per day); SA7: 80 % intake of
dairy products based on current levels of calcium and vitamin
D intake in France [8]; SA8: 50 % intake of dairy products;
SA9: therapy cost for all patients but benefits for 75 %; SA10:
no increased fracture risk after previous fractures; SA11: an
Table 2 Fracture incidence in the
general French population aged
over 60 years
Fracture incidence
(per 1000) (age in years)
Women Men
Hip CV Wrist Others Hip CV Wrist Others
60–74 0.117 0.181 0.313 0.394 0.074 0.135 0.100 0.528
75–84 0.689 0.551 0.551 1.311 0.323 0.298 0.077 0.861
≥85 2.312 1.087 0.986 3.884 1.255 0.842 0.230 3.682
CV clinical vertebral
Table 1 Population estimates
(2015) and projections for 2025
and 2050 in the general French




2015 2025 2050 2015 2025 2050
60–69 3,961,492 4,171,501 4,038,239 3,614,450 3,783,468 3,921,701
70–79 2,507,933 3,663,128 3,786,400 2,036,842 3,045,407 3,321,749
≥80 2,458,810 2,679,558 4,832,570 1,324,216 1,525,294 3,109,529
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additional 8 % costs for marketing and education costs to raise
consumer awareness and ensure their acceptance, based on a
German study estimate [15]. Results of the sensitivity analy-
ses are presented in tornado diagrams.
Results
Table 3 summarizes the projected health impact of the recom-
mended intake of fortified dairy products compared to the
absence of appropriate intake for women and men aged over
60 years in 2015 in France. The total lifetime number of frac-
tures was reduced by 64,932 for the recommended intake of
dairy products in the general population over 65 years, of
which 46,473 and 18,460 occurred in women and men, re-
spectively. In particular, 15,087 and 4413 hip fractures could
be prevented in women and men. The intake of dairy products
resulted in a QALY gained of 32,569 and a gain of 29,169 life
years. Most of the benefits of fortified dairy products occurred
in women and men aged over 80 years, respectively, 62 and
55% of fractures prevented can be found in these populations.
Results of the sensitivity analysis assuming an adherence level
of 82 % can be found in online supplement.
In Table 4, projections of the health impact of fortified
dairy products for the years 2025 and 2050 are presented.
Taken into account demographic changes only, we estimated
that 19 and 78 % more fractures could be prevented with
appropriate intake of fortified dairy products in the years
2025 and 2050, respectively.
The total cost impact of the two extra vitamin D fortified
dairy products/day compared with usual intake was estimated
for the year 2015 at €1555 million in the general population
aged over 60 years. The cost of dairy products was estimated
at €2570 million and €1014 million were saved because of
less fractures resulting from intervention efficacy. Overall,
39% of the cost of dairy products would then be compensated
by saved costs resulting from fewer fractures.
The incremental cost-effectiveness ratio (expressed in cost
per QALY gained) of appropriate intake of fortified dairy
products compared with the absence of appropriate intake is
reported in Table 5. The ICER is estimated at €58,244 per
QALY gained in the French population aged over 60 years.
The ICER was €38,526 and €106,113 in women and men,
respectively. The ICER was below the threshold of €30,000
per QALY gained in women aged above 70 years and in men
aged over 80 years. Projections of cost-effectiveness suggest
that the ICER in the general population aged above 60 years
would decrease to €55,953 in the year 2025 and to €43,620 in
2050. Sensitivity analyses assuming the cost of one and three
dairy products per day are also included in Table 5. One for-
tified dairy product per day is highly cost-effective in the
French general population aged above 60 years (ICER of
€10,121 per QALY gained).
Table 3 Projected health impact
of vitamin D-fortified dairy prod-
ucts in the general population














Hip 844 3729 10,514 15,087 437 1198 2778 4413
CV 1169 2087 4197 7452 846 851 1326 3023
Wrist 1490 1959 2646 6094 351 196 491 1037
Other 2199 4284 11,357 17,839 2440 2047 5499 9986
Total 5701 12,058 28,714 46,472 4073 4292 10,094 18,460
QALY gained 4474 6919 11,674 23,067 2958 2795 3748 9502
Life years
gained
4946 5177 9256 19,378 3889 2693 3209 9791
CV clinical vertebral, QALY quality-adjusted life years, Y years
Table 4 Projection of health impact of dairy products in the general
population aged over 60 years in France for the years 2025 and 2050
Women Men
2015 2025 2050 2015 2025 2050
Lifetime fractures prevented
Hip 15,087 17,793 27,155 4413 5449 8952
CV 7452 8852 12,591 3023 3685 5419
Wrist 6094 7313 9675 1037 1225 1853
Other 17,839 20,949 31,030 9986 11,949 18,899
Total 46,472 54,907 80,451 18,460 22,308 35,123
QALY gained 23,067 27,539 37,951 9502 11,594 16,570
Life years gained 19,378 22,856 31,049 9791 11,794 16,146
CV clinical vertebral, QALY quality-adjusted life years
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One-way sensitivity analyses are included as tornado dia-
grams in Fig. 1. The largest change in terms of public health
impact (number of fractures prevented or QALYs gained) oc-
curred when reducing dairy products intake (to 50 %) follow-
ed by decreasing therapy efficacy or all fracture risk by 25 %
(Fig. 1a, b). The cost-effectiveness of the recommended dairy
intake is strongly influenced by the cost of fortified dairy
products, the effectiveness of calcium and vitamin D, and
the fracture risk of the population.
Discussion
Our study suggests that an adequate intake of calcium and
vitamin D by the administration of vitamin D fortified dairy
products could substantially reduce the burden of osteoporotic
fractures in France. We estimated that the recommended in-
take of fortified dairy products in the year 2015 would lead to
a lifetime decrease of 64,932 fractures including 19,500 hip
fractures. Given 65,697 hip fractures occurred in the year
2013 in France [2], the benefit of fortified dairy products is
therefore substantial. Projections suggest that the number of
prevented fractures through appropriate intake of dairy prod-
ucts could even increase by 78 % in the year 2050 taken into
account demographic changes.
In addition, we estimated the cost-effectiveness of the rec-
ommended intake of vitamin D-fortified dairy products com-
pared to the absence of dietary intake. To draw a conclusion
about the cost-effectiveness, the cost per QALY gained has to
be compared with a cost-effectiveness threshold. This thresh-
old represents the maximum amount that the decision makers
are willing to pay. In France, as in most countries, there is no
consensus on cost-effectiveness. In the overall French popu-
lation aged 60 years and over, we found a cost per QALY
gained of €58,244, in the range of commonly accepted thresh-
old for cost-effectiveness. The intake of fortified dairy prod-
ucts becomes highly cost-effective (cost per QALY <€30,000)
in women over 70 years and in men over 80 years.
Similarly, Ethgen et al. also showed that the intake of dairy
products is cost-effective in the general population over
70 years in Belgium [31]. Our study is more conservative as
we did not incorporate any treatment effect after the year of
the intake of fortified dairy products. A large public health
benefit expressed in life years and fractures prevented, was
also estimated in another Belgian study [14]. However, a dif-
ferent approach was used to assess the public health burden
making comparison with our study difficult. In a recent
German study, Sandman et al. [15] suggested that the imple-
mentation of dietary vitamin D and calcium food-fortification
program in the German population aged 65 years and older
would even lead to annual net cost savings. Lower cost for
dietary products was used in this study which could explain
the more positive benefit of the intervention.
Our study therefore suggests that an adequate intake of
calcium and vitamin D by the administration of vitamin D-
fortified dairy products could lead to a substantial decrease in
the burden of osteoporotic fractures and could be justified
from an economic perspective in women over 70 years and
in men over 80 years (assuming a threshold of €30,000 per
QALY gained). Decision makers should be aware of the ben-
efits of calcium and vitamin D and could be interested to
implement programs to increase the intake of dairy products.
Such programs have already been implemented in some coun-
tries [32, 33]. Clinicians should also take actions to improve
the consumption of fortified dairy products by their patients.
There are some potential limitations to our study. First, our
study was limited to the potential benefits of calcium and
vitamin D on fracture prevention and we could have
Table 5 Cost-effectiveness
(expressed in cost per QALY
gained) of the recommended
intake of vitamin D-fortified dairy
products compared to usual care
in the French general population
aged over 60 years
Population One dairy product per day Two dairy products per day Three dairy products per day
Overall €10,121 €58,244 €106,367
Women
60–69 €67,640 €155,006 €242,272
70–79 Cost-savinga €24,997 €60,719
80+ Cost-saving €1907 €22,663
All ages €382 €38,526 €76,670
Men
60–69 €97,772 €218,176 €338,581
70–79 €20,868 €92,676 €164,484
80+ Cost-saving €27,683 €62,501
All ages €33,766 €106,113 €178,460
Projections (overall)
2025 €8436 €55,953 €103,470
2050 €2028 €43,620 €85,212
a Cost-saving means that intervention costs are lower than saved costs resulting from less fractures
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underestimated the benefits of the intervention. There are oth-
er potential benefits of calcium and vitamin D including the
reduction on the risk for breast cancer in premenopausal wom-
en and colon cancer in older women [34]. Dairy products are
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SA1: all fracture risk +25%
SA3: therapy efficacy +25%
SA10: no increased fracture risk after previous fractures
SA7: 80% of dairy products intake
SA9: therapy cost for all patients but benefits for 75%
SA4: therapy efficacy -25%
SA2: all fracture risk -25%
SA8: 50% of dairy products intake
Lifetime fractures prevented 
A Base case: 64,932
SA5, SA6 and SA11 have no impact on the lifetime QALYs gained 
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SA10: no increased fracture risk after previous fractures 
SA7: 80% of dairy products intake
SA2: all fracture risk -25%
SA9: therapy cost for all patients but benefits for 75%
SA4: therapy efficacy -25%
SA8: 50% of dairy products intake
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SA5: therapy cost +50%
SA4: therapy efficacy -25%
SA9: therapy cost for all patients but benefits for 75%
SA2: all fracture risk -25%
SA11: marketing/education costs +8%
SA10: no increased fracture risk after previous fractures 
SA3: therapy efficacy +25%
SA1: all fracture risk +25%
SA6: therapy cost -50%
Cost per QALY gained
C Base case: 58,244
Fig. 1 Tornado diagrams for one-
way sensitivity analyses on the
health impact expressed in
lifetime number of fractures
prevented (Fig. 1a), in QALYs
gained (Fig. 1b), and on the cost-
effectiveness (expressed in cost
per QALY gained) of vitamin D-
fortified dairy products (Fig. 1c)
in the general population aged
over 60 years in France in the year
2015. SA5, SA6, and SA11 have
no impact on the lifetime number
of fractures prevented
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also rich in proteins which could also lead to extra health
benefits [35]. A meta-analysis also indicated that vitamin
D may have a small beneficial effect on cardiovascular
risk and mortality [36]. On the other hand, we did not in-
corporate any adverse events although the risk seems limited
[37]. Second, a few patients already have an adequate level of
calcium and vitamin D through nutrients [5, 6]. On the oppo-
site, the benefits for some patients with large insufficiency in
vitamin D and/or calcium could be even larger than the as-
sumed effect. Having an adequate level of calcium and vitamin
D could also lead to higher benefits of pharmacological treat-
ment for osteoporosis [14]. We could reasonably assume that
all these effects could compensate each other. Third, we did not
specifically incorporate adherence to fortified dairy products in
the analysis. Little is known about adherence to fortified dairy
products and how this could affect intervention efficacy. In
sensitivity analyses, we assumed that only 80 or 50 % of pa-
tients would be willing to consume fortified dairy products.
Further studies are needed to assess adherence to fortified dairy
products and willingness of the French population to consume
fortified dairy products. Lastly, the effect of calcium and vita-
min D on fracture risk reduction was derived from a Cochrane
Review that was based on all trials about calcium and vitamin
D compounds [30]. Further studies are needed to assess the
effects of calcium and vitamin D by the administration of for-
tified dairy products.
In conclusion, this study suggests that the intake of vitamin
D fortified dairy products have the potential to substantially
reduce the burden of osteoporotic fractures and could be an
economically beneficial strategy in France, especially in the
general population aged above 70 years.
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